# Targeting Latexin for radiation mitigation.

> **NIH NIH R43** · P2D, INC. · 2020 · $284,306

## Abstract

The purpose of this grant is to develop novel therapeutic approaches for
radiological/nuclear medical countermeasures. Very few medical products have been
shown to counter the acute and long-term injuries that can result from a nuclear or
radiological accident or attack. Medical products and regimens that mitigate and/or treat
radiation injury post-exposure (i.e., administration of first dose to start at least 24 hours
after radiation exposure), with emphasis on ease of administration in a mass casualty
and emergency scenario; safety; and long shelf-life are still to be developed and are thus
of high priority. Therapeutic administration of a drug that inhibits the activity of the
protein latexin in hematopoietic stem cells (HSCs) resulted in mitigation of HSC function.
These findings suggest that pharmacologic augmentation of the activity of such a drug,
in combination with additional mitigators currently developed, might offer a rational
approach to the mitigation of tissue injury and lethality caused by ionizing radiation that
especially affects hematopoiesis.

## Key facts

- **NIH application ID:** 9925204
- **Project number:** 5R43AI145726-02
- **Recipient organization:** P2D, INC.
- **Principal Investigator:** SOMASUNDAR PRASAD GABBITA
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $284,306
- **Award type:** 5
- **Project period:** 2019-05-06 → 2022-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9925204

## Citation

> US National Institutes of Health, RePORTER application 9925204, Targeting Latexin for radiation mitigation. (5R43AI145726-02). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/9925204. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*